BEZALIP

This brand name is authorized in Austria, Canada, Finland, Hong Kong, Malta, Netherlands, New Zealand, United Kingdom, South Africa

Active ingredients

The drug BEZALIP contains one active pharmaceutical ingredient (API):

1 Bezafibrate UNII Y9449Q51XH - BEZAFIBRATE

Bezafibrate lowers elevated blood lipids (triglycerides and cholesterol). Elevated VLDL and LDL are reduced by treatment with bezafibrate, whilst HDL-levels are increased. Furthermore, cholesterol biosynthesis is reduced by bezafibrate, which is accompanied by a stimulation of the LDL receptor-mediated lipoprotein catabolism. Read about Bezafibrate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AB02	Bezafibrate	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02083523
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 565440
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 13454, 138365, 13938, 142864, 161425, 184895
Country: HK	Department of Health Drug Office	Identifier(s): 31358, 31359
Country: MT	Medicines Authority	Identifier(s): AA565/64001, AA729/24701
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 43435
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 3718, 3720
Country: ZA	Health Products Regulatory Authority	Identifier(s): Q/7.5/104, S/7.5/270